Stay updated on Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial
Sign up to get notified when there's something new on the Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial page.

Latest updates to the Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial page
- CheckyesterdayChange DetectedThe page has updated its date information, adding several future dates while removing some past dates. Notably, the new dates include events scheduled for May 2025 and July 2026.SummaryDifference1%
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed descriptions of a phase 2 study on cirmtuzumab and venetoclax, while adding references to Chronic Lymphocytic Leukemia and collaborators involved in the study.SummaryDifference26%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check44 days agoChange DetectedDifference0.7%
- Check52 days agoChange DetectedDifference0.7%
Stay in the know with updates to Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial page.